UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 2)*

FATE THERAPEUTICS INC

(Name of Issuer)

Common Stock (Title of Class of Securities)

31189P102

(CUSIP Number)

December 31, 2019

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

x Rule 13d-1(b)

□ Rule 13d-1(c)

□ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 2 of 4 Pages

1. NAMES OF REPORTING PERSONS					
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Victory Capital Management Inc.					
13-2700161	i management inc.				
	(see instructions)				
	(b) □ 3. SEC USE ONLY				
5. 510 001 0111					
4. CITIZENSHIP C	OR PLACE OF ORGANIZATION				
New York					
	5. SOLE VOTING POWER				
	4,092,794				
NUMBER OF	6. SHARED VOTING POWER				
SHARES BENEFICIALLY	0				
OWNED BY EACH	7. SOLE DISPOSITIVE POWER				
REPORTING					
PERSON WITH	4,229,154 8. SHARED DISPOSITIVE POWER				
	0				
9. AGGREGATE A	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
5. MOOREOMEN					
4,229,154					
	AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				
(see instructions)					
11. PERCENT OF C	LASS REPRSENTED BY AMOUNT IN ROW (9)				
5 500/					
5.59%					
12. TYPE OF REPO	RTING PERSON (see instructions)				
10					
IA					

CUSIP No. 26927E104

Page 3 of 4 Pages

Item 1.

(a) Name of Issuer

- FATE THERAPEUTICS INC
- (b) Address of Issuer's Principal Executive Offices 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121

Item 2.

(a) Name of Persons Filing Victory Capital Management Inc.

- (b) Address of the Principal Office or, if none, residence 4900 Tiedeman Rd. 4th Floor Brooklyn, OH 44144
- (c) Citizenship New York
- (d) Title of Class of Securities Common Stock
- (e) CUSIP Number 31189P102

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) 🗌 Broker or dealer registered under section 15 of the Act (15 U.S.C. 780).
- (b) \Box Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) 🗌 Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d) 🔲 Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e) **x** An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g) \Box A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
- (h) 🗌 A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) 🗌 A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) \Box Group, in accordance with §240.13d-1(b)(1)(ii)(J).

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)	Amount beneficially owned: 4,229,154	
(b)	Percent of class: 5.59%	
(C)	Number of shares as to which the person has:	
	(i)	Sole power to vote or to direct the vote: 4,092,794
	(ii)	Shared power to vote or to direct the vote: 0
	(iii)	Sole power to dispose or to direct the disposition of: 4,229,154
	(iv)	Shared power to dispose or to direct the disposition of: 0

Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following \Box .

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

The clients of Victory Capital Management Inc., including investment companies registered under the Investment Company Act of 1940 and separately managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the class of securities reported herein of FATE Therapeutics.. No client has the right to receive or the power to direct the receipt of dividends from, or the proceeds from, or the proceeds from the sale of, more than 5% of such class.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

CUSIP No. 31189P102

13G

Page 4 of 4 Pages

Item 10. Certification.

(a) The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

1/31/2020
Date
/s/ Colin S. Kinney
Colin S. Kinney/Chief Compliance Officer